We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

Statements | Media| Grünenthal Group
;

Media Statements

11/29/2019

We have recorded numerous media reports about the intent of the German Contergan Foundation to cease payments to people affected by "Sedalis". Grünenthal's position on this matter is as follows:

The responsible bodies of the Contergan Foundation decided almost fifty years ago that "Sedalis" is a product that is captured by the Contergan Foundation Law. We see no reason to doubt this assessment. Whilst we disagree with the intent of the Contergan Foundation, we have no influence on it nor were we informed about this intent in advance.

Štěpán Kráčala

Head Global Communications

Grünenthal GmbH


Aachen

E-Mail Stepan.Kracala@grunenthal.com

Phone +49 241 569-1335